1. Target engagement of the systemic Stat3 inhibitor in APP/PS1 mice
Target engagement of the systemic Stat3 inhibitor in APP/PS1 mice A–DSH‐4‐54 significantly decreased plaque growth, as assessed by IC16 immunohistochemistry, while plaque load remained unchanged. There was also no significant change in dystrophic neurite area during the treatment time (Mann–Whitney test for all comparisons; scale bars, 500 μm).E–GThe fraction of pStat3‐positive astrocytes in the peri‐plaque region was strongly reduced by the treatment with the Stat3 inhibitor (arrowheads indicate pStat3 signals; scale bars, 100 μm; Mann–Whitney test).H–KWhile no changes were seen in morphological parameters of peri‐plaque astrocytes, there was a significant increase in the process length of near‐plaque microglia, indicating higher microglial complexity (Mann–Whitney test for all comparisons).Data information: Data are represented as mean ± SEM. APP/PS1 mice treated with SH‐4‐54, n = 12 (six females and six males) mice; APP/PS1 mice treated with vehicle, n = 12 (7 females and 5 males) mice; age, 8 months.
Nicole Reichenbach et al. EMBO Mol Med. 2019;emmm
© as stated in the article, figure or figure legend